Sanger D.J.
Synthélabo Recherche, 31 ave P.V. Couturier, 92220-Bagneux, France.
Behav Pharmacol. 1995 Mar;6(2):116-126.
In recent years a number of novel compounds have been described with affinity and specificity for BZ (omega) receptors. While some of these agents appear to act, like benzodiazepines themselves, as full agonists at different receptor subtypes (e.g. suriclone), several non-selective partial agonists (e.g. bretazenil) have been described, as have a number of BZ(1) (omega(1)) selective drugs (e.g. zolpidem). Previous work has reported a number of differences between the behavioural effects of some of these drugs and those of benzodiazepines; however, very few studies have attempted systematic comparisons of a large number of drugs in different procedures. In the present study a wide range of BZ (omega) receptor ligands was studied using two behavioural methods in rats: unpunished and punished food-reinforced operant responding and the discriminative stimulus effects of pentylenetetrazole. Punished operant responding showed increases with the benzodiazepines, chlordiazepoxide and clorazepate, the non-benzodiazepines, saripidem, CL 273,547 and F 2692 (limited effect at a single dose) and the partial agonists bretazenil and Ro 19-8022, but the BZ(1) selective agents, alpidem, abecarnil and CL 284,846, did not increase rates of punished operant responding. Rates of unpunished responding were decreased by higher doses of all drugs except bretazenil and Ro 19-8022. Dose-related antagonism of the pentylenetetrazole (18mg/kg) discriminative stimulus was produced by several benzodiazepines, by the partial agonists bretazenil, Ro 19-8022 and divaplon, and by suriclone, saripidem and CL 273,547. The BZ(1) (omega(1)) selective drugs abecarnil, CL 284,846, zolpidem, CL 218,872 and alpidem were also active in blocking pentylenetetrazole but produced only partial antagonism which was not clearly dose-related. The results show that novel BZ (omega) receptor ligands do not always produce a behavioural profile identical to that shown by benzodiazepines. In particular, BZ(1) (omega(1)) selective drugs do not give rise to clear increases in punished operant responding and have only limited efficacy in blocking the pentylenetetrazole cue. These effects may be due to the marked propensity of BZ(1) (omega(1)) selective drugs to decrease operant response rates.
近年来,已描述了多种对BZ(ω)受体具有亲和力和特异性的新型化合物。虽然其中一些药物似乎像苯二氮䓬类药物本身一样,在不同受体亚型上作为完全激动剂起作用(例如舒立克隆),但也已描述了几种非选择性部分激动剂(例如布雷他尼),以及一些BZ(1)(ω(1))选择性药物(例如唑吡坦)。先前的研究报道了其中一些药物与苯二氮䓬类药物在行为效应上的一些差异;然而,很少有研究尝试在不同程序中对大量药物进行系统比较。在本研究中,使用两种行为方法对大鼠中的多种BZ(ω)受体配体进行了研究:未受惩罚和受惩罚的食物强化操作性反应,以及戊四氮的辨别刺激效应。受惩罚的操作性反应在给予苯二氮䓬类药物氯氮卓和氯氮䓬、非苯二氮䓬类药物沙立吡坦、CL 273,547和F 2692(单剂量时作用有限)以及部分激动剂布雷他尼和Ro 19-8022后增加,但BZ(1)选择性药物阿吡坦、阿贝卡尼和CL 284,846并未增加受惩罚的操作性反应率。除布雷他尼和Ro 19-8022外,所有药物的较高剂量均降低了未受惩罚的反应率。几种苯二氮䓬类药物、部分激动剂布雷他尼、Ro 19-8022和地伐普隆,以及舒立克隆、沙立吡坦和CL 273,547产生了与戊四氮(18mg/kg)辨别刺激相关的剂量依赖性拮抗作用。BZ(1)(ω(1))选择性药物阿贝卡尼、CL 284,846、唑吡坦、CL 218,872和阿吡坦在阻断戊四氮方面也有活性,但仅产生部分拮抗作用,且与剂量无明显相关性。结果表明,新型BZ(ω)受体配体并不总是产生与苯二氮䓬类药物相同的行为特征。特别是,BZ(1)(ω(1))选择性药物不会使受惩罚的操作性反应明显增加,并且在阻断戊四氮提示方面的功效有限。这些效应可能是由于BZ(1)(ω(1))选择性药物显著倾向于降低操作性反应率所致。